Wednesday, October 14, 2026 | 10:40 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Pharma

Sun Pharma board approves plan to raise up to ₹10,000 crore via NCDs

Sun Pharmaceutical Industries has said its board of directors has approved a proposal to raise funds of up to Rs 10,000 crore through the issuance of non-convertible debentures (NCDs). The decision was taken at a meeting of the company's Board of Directors held on October 12, Sun Pharma said in a regulatory filing late on Monday evening. The board approved the issuance of listed, rated, unsecured, redeemable NCDs on a private placement basis in one or more tranches and/or series for an aggregate amount not exceeding Rs 10,000 crore. The company said that disclosures required under Regulation 30 of the Sebi (Listing Obligations and Disclosure Requirements) Regulations, 2015, will be made at an appropriate stage upon the issuance or allotment of the debentures. Separately, the company announced that Gautam Doshi has resigned as a Non-Executive, Independent Director with immediate effect, citing personal reasons. Consequent upon his resignation, he has also ceased to hold positions on

Sun Pharma board approves plan to raise up to ₹10,000 crore via NCDs
Updated On : 13 Oct 2026 | 2:34 PM IST

Centre to cap trade margins on non-scheduled cancer drugs at 30%

Move could cut MRPs by up to 70%, save patients ₹2,500 crore annually; comes amid SC scrutiny of high mark-ups

Centre to cap trade margins on non-scheduled cancer drugs at 30%
Updated On : 09 Oct 2026 | 12:17 AM IST

Neuberg, NM Medical consolidate Maharashtra operations, eye wider reach

The combined Maharashtra business is expected to generate around ₹500 crore in revenue this year, with plans to establish a presence in every district headquarters

Neuberg, NM Medical consolidate Maharashtra operations, eye wider reach
Updated On : 06 Oct 2026 | 7:26 PM IST

Pharma dept to offer gap funding for early-stage novel drug discovery

Funding will be part of a new track under the PRIP scheme exclusively for start-ups and MSMEs at the initial research stage, with assistance of up to ₹50 crore per project

Pharma dept to offer gap funding for early-stage novel drug discovery
Updated On : 30 Sep 2026 | 10:22 PM IST

A dose of innovation

Pharma sector needs a supportive environment

A dose of innovation
Updated On : 09 Sep 2026 | 10:01 PM IST

Novartis India buys Minipress brands from Pfizer for ₹1,250 crore

The company's board approved the transaction on Monday, following which Novartis India executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc and Pfizer Products Inc

Novartis India buys Minipress brands from Pfizer for ₹1,250 crore
Updated On : 07 Sep 2026 | 6:10 PM IST

Innovative ecosystem will make India attractive: Judith Love & Amitabh Dube

Novartis doubles down on innovation in India, eyeing R&D, clinical trials and a stronger regulatory ecosystem while moving away from traditional generics

Innovative ecosystem will make India attractive: Judith Love & Amitabh Dube
Updated On : 07 Sep 2026 | 6:05 AM IST

Indian pharma market rises 12.1% in July on broad-based therapy growth

The market recorded sales of Rs 23,193 crore in July, with cardiac and anti-diabetic therapies posting double-digit growth and four leading segments accounting for 46.6 per cent

Indian pharma market rises 12.1% in July on broad-based therapy growth
Updated On : 07 Aug 2026 | 8:41 PM IST

Supriya Lifescience tanks 12%; what's ailing this pharma stock?

Supriya Lifescience said proceedings were initiated against the personnel of the company under the NDPS Act, 1985 for a procedural lapse for a single export transaction of an identified producer.

Supriya Lifescience tanks 12%; what's ailing this pharma stock?
Updated On : 06 Jul 2026 | 2:55 PM IST

Zydus, Sunshine Healthcare form JV for pharma manufacturing in Sri Lanka

Zydus Lifesciences and Sri Lanka's Sunshine Healthcare on Friday announced the setting up of a joint venture with an investment commitment of over USD 20 million to establish a pharmaceutical manufacturing facility in the island nation. The company has entered into a share subscription and shareholders' agreement (SSSHA) with Sunshine Healthcare Lanka Ltd (Sunshine) and Zydus Sunshine Lifesciences (Pvt) Ltd (Zydus Sunshine), Zydus Lifesciences said in a regulatory filing. Under the SSSHA, Zydus Lifesciences will subscribe 50 per cent of the total paid-up equity share capital of Zydus Sunshine for up to USD 5 million in one or more tranches, it added. Zydus Sunshine will set up a manufacturing facility in Horana Export Processing Zone in Sri Lanka to manufacture pharmaceutical products, which will strengthen local production and reduce import dependence, the filing said. This will improve access to high-quality medicines while supporting national supply chain resilience, it ...

Zydus, Sunshine Healthcare form JV for pharma manufacturing in Sri Lanka
Updated On : 26 Jun 2026 | 3:42 PM IST

Hyderabad firm builds over ₹400 crore pharma biz, without a factory

HRV Pharma owns drug master files and customer relationships while outsourcing production to 53 manufacturing partners, aiming to scale without owning factories

Hyderabad firm builds over ₹400 crore pharma biz, without a factory
Updated On : 22 Jun 2026 | 12:00 AM IST

Zaynich antibiotic: How Wockhardt created India's first FDA-approved drug | Pharma Industry

For decades, India excelled at making affordable generic medicines. But creating a brand-new drug from scratch remained a rare achievement. Now, Wockhardt has made history with Zaynich

Icon YoutubeZaynich antibiotic: How Wockhardt created India's first FDA-approved drug | Pharma Industry
Updated On : 15 Jun 2026 | 6:18 PM IST

Cancer drug shortage: Drugmaker Naprod seeks one-time price hike

Says higher import duties, regulatory hurdles have made chemo drugs' production unviable

Cancer drug shortage: Drugmaker Naprod seeks one-time price hike
Updated On : 10 Jun 2026 | 2:36 PM IST

Indian drugmakers deepen US bets despite decline in pharma exports

Indian pharmaceutical companies are investing in specialty drugs, biosimilars and local manufacturing in the US despite a near 10 per cent fall in exports in FY26

Indian drugmakers deepen US bets despite decline in pharma exports
Updated On : 25 May 2026 | 10:45 PM IST

HAB Pharma targets ₹3,000 crore revenue by 2030 after merger deal

HAB Pharmaceuticals aims to scale operations and expand globally after merging with Signature Phytochemical Industries through a slump sale deal

HAB Pharma targets ₹3,000 crore revenue by 2030 after merger deal
Updated On : 19 May 2026 | 10:25 PM IST

India joins weight-loss drug race, but affordability remains a concern

India is in the race for a new class of weight-loss drugs, but the question is: Will they be affordable?

India joins weight-loss drug race, but affordability remains a concern
Updated On : 12 May 2026 | 12:18 AM IST

Sun Pharma bets on Organon front-end to drive global growth, efficiencies

Sun Pharma sees its Organon acquisition as a platform to expand globally, boost in-licensing, and improve long-term efficiencies through a stronger commercial front-end

Sun Pharma bets on Organon front-end to drive global growth, efficiencies
Updated On : 29 Apr 2026 | 11:58 PM IST

Will AI Change Healthcare Forever? Future of India’s Pharma Shift

In this exclusive conversation with Business Standard, Sujit Paul, CEO of Zota Healthcare and the driving force behind DavaIndia, shares bold views on the future of healthcare

Icon YoutubeWill AI Change Healthcare Forever? Future of India’s Pharma Shift
Updated On : 28 Apr 2026 | 5:13 PM IST

Cohance Lifesciences appoints Umang Vohra as chairman, CEO; Sharma exits

Pharma veteran Umang Vohra to lead Advent-backed Cohance Lifesciences as chairman and CEO, succeeding Vivek Sharma amid efforts to revive growth and address regulatory challenges

Cohance Lifesciences appoints Umang Vohra as chairman, CEO; Sharma exits
Updated On : 27 Apr 2026 | 4:43 PM IST

Q4 Earnings Outlook: IT, Auto, Pharma, FMCG, Metals — What to expect | Business News | Share market

India Inc heads into the Q4 FY26 earnings season navigating a complex mix of geopolitical tensions, uneven demand trends, and cost pressures.

Icon YoutubeQ4 Earnings Outlook: IT, Auto, Pharma, FMCG, Metals — What to expect | Business News | Share market
Updated On : 27 Apr 2026 | 12:43 PM IST